United Therapeutics stock

UTHR · NASDAQ · USD

Compare United Therapeutics
$584.10Change from previous close: −0.64%Absolute change: −$3.78

Close · November 17, 2026

Price history

+22.52% over the period

1 year: from $471.92 (November 17, 2025) to $578.20 (November 17, 2026), +22.52%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$578.20
October 30, 2026$598.72
September 30, 2026$541.89
August 31, 2026$510.38
July 31, 2026$517.71
June 30, 2026$541.83
May 29, 2026$556.82
April 30, 2026$571.35
March 31, 2026$592.98
February 27, 2026$503.90
January 30, 2026$469.49
December 31, 2025$487.25
November 28, 2025$486.00
November 17, 2025$471.92

At a glance

  • The company

    Develops and commercializes drugs and organ transplant products for pulmonary arterial hypertension, neuroblastoma, pulmonary fibrosis and related diseases

  • Latest results

    Quarter to September 30, 2026 · EPS $5.71 (estimate $6.21)

TickerLandia's take on United Therapeutics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$455.63
52-wk high$614.23

−4.91% from the 52-week high

Analysts · 15 analysts

Average target$687.14+17.64% vs. price

Buy 12 · Hold 2 · Sell 1 · Buy

TickerLandia Fingerprint: United Therapeutics

Compared with similar companies: very high profitability and very high financial strength.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

United Therapeutics is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), United Therapeutics's P/E today is 20.8, above the median of its last 9 fiscal years (14.3; between 8.13 and 21.5 from 2016 to 2025). United Therapeutics's P/E (trailing 12 months): 22.2, −20% against the median of a group of 9 similar companies (27.6).

P/E compared with its history

Compared with 9 similar companies

United Therapeutics's metrics compared with similar companies
MetricUnited TherapeuticsPosition in the groupBand
P/E (trailing 12 months)22.2Middle
Forward P/E17.0Middle
Operating margin39.4%High
ROE19.1%Middle
Price/book3.97Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: United Therapeutics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$832.5M

Latest quarter · Q3 2026

Net income

$258.6M

Latest quarter · Q3 2026

Quarterly net margin

31.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$25.04B
P/E
22.2
EPS
$26.49
Volume
424.5K
Daily trading
€279.36M
Dividend yield
0.00%

How United Therapeutics is changing

All results
  • Revenue grew 16.5% a year on average over the last 5 years

  • Operating margin fell from 50.6% to 46.9%

  • Free cash flow equal to 82% of net income

Returns

United Therapeutics returns

$1,000 invested in United Therapeutics 5 years ago, on November 17, 2021, would be worth $2,900 today: +189.95% in total, +23.73% per year. This is the price return only: dividends are excluded.

PeriodUnited TherapeuticsS&P 500$1,000 becomes
1 month+6.45%−3.17%$1,065
6 months+2.73%+0.11%$1,027
Year to date+18.66%+8.34%$1,187
1 year+22.52%+11.15%$1,225
3 years+152.55%+64.30%$2,526
5 years+189.95%+58.18%$2,900
10 years+333.07%+239.10%$4,331

Over the last 6 months it has done better than 27% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

United Therapeutics: technical analysis

United Therapeutics is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.0% below its all-time closing high ($608.49, November 4, 2026).

Trend
Upward
RSI (14 sessions)
55
Between 30 and 70
vs 200-session average
+8.45%

Active signals

  • Golden cross: the 50-session average has crossed above the 200-session average.

    since November 9, 2026

Support and resistance

Price areas where United Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$610.49+4.52%3 touches, last on November 4, 2026
  2. Last price$584.10
  3. Support$583.09−0.17%2 touches, last on October 1, 2026
  4. Support$557.96−4.47%6 touches, last on November 9, 2026
  5. Support$535.55−8.31%6 touches, last on August 27, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.41
Volatility (60 sessions, annualised)
40.2%
Largest fall in the last year
−20.87%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

United Therapeutics: seasonality

Average monthly price change over 28 years

+0.5%Jan+2.2%Feb+1.4%Mar−2.2%Apr+4.7%May+2.7%Jun+4.1%Jul+5.0%Aug+1.7%Sep+0.1%Oct+5.5%Nov+3.0%Dec

Over the last 28 years, the strongest month for United Therapeutics has been November: +5.55% on average, positive in 17 years out of 27. The weakest has been April: −2.20% on average, positive in 11 years out of 27.

Show chart data
MonthAverageMedianPositive years
January+0.53%−1.42%12 of 27
February+2.19%+0.23%14 of 27
March+1.35%−0.61%13 of 27
April−2.20%−1.68%11 of 27
May+4.70%+4.11%15 of 27
June+2.69%+2.30%14 of 27
July+4.09%+1.46%16 of 28
August+4.96%−0.57%14 of 28
September+1.74%−0.74%13 of 28
October+0.08%+3.10%18 of 28
November+5.55%+4.28%17 of 27
December+2.99%+1.66%16 of 27

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

United Therapeutics and its competitors

Based in Silver Spring, Maryland, United Therapeutics Corporation has existed since 1996 and develops and commercializes products for patients with chronic and life-threatening diseases. Its treatments for pulmonary arterial hypertension form the core of its range, including the inhaled Tyvaso DPI and Nebulized Tyvaso, the injectable Remodulin, the tablet Orenitram and the oral Adcirca. It also sells Unituxin, a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump, a pump and controller for Remodulin.

Headquarters
Silver Spring, United States
Employees
1,400
Founded
1996
Chief executive
Martine Rothblatt
United Therapeutics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
United TherapeuticsUTHR$25.04B39.4%22.2+2.73%
ViatrisVTRS$23.58B——+24.09%
ZoetisZTS$33.92B37.9%14.1+12.48%
Neurocrine BiosciencesNBIX$16.73B26.6%24.5+4.73%
Teva Pharmaceutical IndustriesTEVA$49.67B19.8%99.0+24.29%
Hims & Hers HealthHIMS$4.13B-6.4%—−29.94%

Same industry or related industries, similar size. Compare United Therapeutics with its competitors · Full profile